Dosimetric Parameters and Clinical Characteristics of Early Stage Breast Cancer Patients Treated with the SAVI Breast Brachytherapy Device

Pinn-Bingham, M.E.; Zhang, J.; Dietrich, S; Braggins, W.; Sehgal, V; Al-Ghazi, M; Wong, J K; Kuo, Jeffrey; Ramsinghani, Nilam

doi:10.1016/j.ijrobp.2011.06.462

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The late complications were pulmonary ( n = 8), esophageal ( n = 6), cardiac ( n = 9), osseous ( n = 6), and a second primary ( n = 2; Lee et al, 2009). A secondary analysis of the CALGB 30105 trial (induction and concurrent chemotherapy with 74 Gy RT) found that, of the cases of RTOG grade 3–5 toxicity, 80% of patients had N3 disease or a V20 >38 (Salama et al, 2011). Graham et al report that the grade 2+ pneumonitis risk is 0% when the V20 is <22, 7% if the V20 is 22–31, 13% if the V20 is 32–40 and 36% if the V20 is >40%.…”

Section: Toxicity Associated With Dose Escalationmentioning

confidence: 99%

Radiation Dose Escalation in Stage III Non-Small-Cell Lung Cancer

Terakedis¹,

Sause²

2011

Front. Oncol.

View full text Add to dashboard Cite

For patients with stage III non-small-cell lung cancer with unresectable or inoperable tumors, definitive chemoradiotherapy is often utilized. Historically, local control and overall survival rates have been poor. In an effort to improve local control, new chemotherapeutic agents in combination with higher doses of radiotherapy have been investigated. Early dose escalation trials date back to the 1980s, and the feasibility and efficacy of dose escalation for patients with inoperable stage III lung cancer continue to be topics of investigation. Herein, we review the evolution of chemotherapy as it relates to treatment of unresectable stage III lung cancer, and we outline the early and the more recent dose escalation studies. While dose escalation appears to provide a modest benefit in terms of preventing local failure and improving overall survival, advances in diagnostic imaging and radiotherapy treatment have possibly resulted in selection of a more favorable patient population. These variables make statements regarding the benefit of dose escalation challenging.

show abstract

Section: Toxicity Associated With Dose Escalationmentioning

confidence: 99%